Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis

Clinical Pharmacokinetics

Volumn 46, Issue 4, 2007, Pages 291-305

  Wagenlehner, Florian M E ^a   Weidner, Wolfgang ^a   Naber, Kurt G ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLAMINOPENICILLIN DERIVATIVE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZLOCILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFALEXIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; DROTRECOGIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NITROFURANTOIN; OFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLONE DERIVATIVE; SULFONAMIDE; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BLOOD PRESSURE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE MARKER; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG MEGADOSE; DRUG RELEASE; DRUG URINE LEVEL; ELECTROLYTE BALANCE; ENTEROBACTER; ESCHERICHIA COLI; GENETIC PREDISPOSITION; GLOMERULUS FILTRATION RATE; HOSPITAL INFECTION; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KLEBSIELLA; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEUS; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPTIC SHOCK; SEX DIFFERENCE; SINGLE DRUG DOSE; SURGICAL DRAINAGE; TABLET FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION;

ANTI-INFECTIVE AGENTS, URINARY; CALCITONIN; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HUMANS; KIDNEY DISEASES; PRACTICE GUIDELINES; PROTEIN PRECURSORS; SEPSIS; URINARY TRACT INFECTIONS;

EID: 33947720138     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746040-00003     Document Type: Review

References (110)

1. Book M, Lehmann LE, Schewe JC, et al. Urosepsis: current therapy and diagnosis [in German]. Urologe A 2005; 44 (4): 413-24
2. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 2000; 26 Suppl. 1: S64-74
3. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348 (16): 1546-54
4. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348 (2): 138-50
5. Brun-Buisson C, Meshaka P, Pinton P, et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30 (4): 580-8
6. Knaus WA, Sun X, Nystrom O, et al. Evaluation of definitions for sepsis. Chest 1992; 101 (6): 1656-62
7. Rosser CJ, Bare RL, Meredith JW. Urinary tract infections in the critically ill patient with a urinary catheter. Am J Surg 1999; 177 (4): 287-90
8. Menninger M. Urosepsis, Klinik, Diagnostik und Therapie. In: Hofstetter A, editor. Urogenitale Infektionen. Berlin, Heidelberg, New York: Springer, 1998: 521-8
9. Wagenlehner FM, Weidner W, Naber KG. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/ pharmacodynamic considerations. J Hosp Infect 2005; 60 (3): 191-200
10. Wagenlehner F, Naber KG. Antibiotics and resistance of uropathogens. European Urology (Update Series) 2004; 2: 125-35
11. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101 (6): 1644-55
12. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31 (4): 1250-6
13. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. Crit Care Med 1992; 20 (6): 724-6
14. Astiz ME, Rackow EC. Septic shock. Lancet 1998; 351 (9114): 1501-5
15. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282 (5396): 2085-8
16. Opal SM, Huber CE. Bench-to-bedside review: Toll-like receptors and their role in septic shock. Crit Care 2002; 6 (2): 125-36
17. Means TK, Golenbock DT, Fenton MJ. Structure and function of Toll-like receptor proteins. Life Sci 2000; 68 (3): 241-58
18. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164 (3): 396-402
19. Naber KG, Madsen PO. Renal function during acute total ureteral occlusion and the role of the lymphatics: an experimental study in dogs. J Urol 1973; 109 (3): 330-8
20. Naber KG, Madsen PO, Maroske D, et al. Antibiotics and chemotherapeutics in renal lymph: an experimental study in dogs. Invest Urol 1976; 14 (1): 23-7
21. Naber K, Madsen PO, Bichler KH, et al. Determination of renal tissue levels of antibiotics [in German]. Infection 1973; 1: 208-13
22. Jaenike JR. The renal response to ureteral obstruction: a model for the study of factors which influence glomerular filtration pressure. J Lab Clin Med 1970; 76 (3): 373-82
23. Gulmi FA FD, Vaughan Jr ED. Pathophysiology of urinary tract obstruction. In: Walsh PC, Retik AB, Vaughan ED, et al., editors. Campbell's urology. 8th ed. Philadelphia: Saunders, 2002: 411-62
24. Naber KG, Kuni H. Renale Pharmakokinetik. Hahnenklee-Symposium 'Pyelonephritis'; 1976 May 20-21; Roche, Basel, 271-85
25. Bricker NS, Morrin PA, Kime Jr SW. The pathologic physiology of chronic Bright's disease: an exposition of the 'intact nephron hypothesis'. Am J Med 1960; 28: 77-98
26. Naber KG, Bishop MC, Bjerklund-Johansen TE, et al. Guidelines on the management of urinary and male genital tract infections. EAU Working Group on Urinary and Male Genital Tract Infections. Arnhem: European Association of Urology, 2006 [online]. Available from URL: http://www.uroweb.nl/files/ uploaded_files/guidelines/15%20Male%20UTI.pdf [Accessed 2007 Feb 26]
27. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340 (3): 207-14
28. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345 (19): 1368-77
29. Gluck T, Opal SM. Advances in sepsis therapy. Drugs 2004; 64 (8): 837-59
30. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288 (7): 862-71
31. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345 (19): 1359-67
32. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29 (11): 2051-9
33. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32 (3): 858-73
34. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30 (4): 536-55
35. Yoshimura K, Utsunomiya N, Ichioka K, et al. Emergency drainage for urosepsis associated with upper urinary tract calculi. J Urol 2005; 173 (2): 458-62
36. Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med 2003; 31 (1 Suppl.): S25-8
37. Eggimann P, Pittet D. Infection control in the ICU. Chest 2001; 120 (6): 2059-93
38. Wagenlehner FM, Krcmery S, Held C, et al. Epidemiological analysis of the spread of pathogens from a urological ward using genotypic, phenotypic and clinical parameters. Int J Antimicrob Agents 2002; 19 (6): 583-91
39. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68 (3): 344-55
40. Kreger BE, Craven DE, Carling PC, et al. Gram-negative bacteremia: III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68 (3): 332-43
41. Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection. J Infect 1997; 35 (3): 283-8
42. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113 (2): 412-20
43. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111 (3): 676-85
44. Singh N, Yu VL. Rational empiric antibiotic prescription in the ICU. Chest 2000; 117 (5): 1496-9
45. Mutlu GM, Wunderink RG. Severe pseudomonal infections. Curr Opin Crit Care 2006; 12 (5): 458-63
46. Frimodt-Møller N. How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents 2002; 19 (4): 333-9
47. Frimodt-Møller N. Correlation between pharmacokinetic/ pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002; 19 (6): 546-53
48. Hvidberg H, Struve C, Krogfelt KA, et al. Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob Agents Chemother 2000; 44 (1): 156-63
49. Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001; 17 (4): 331-41
50. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 2001; 69 (7): 4572-9
51. Ivanyi B, Rumpelt HJ, Thoenes W. Acute human pyelonephritis: leukocytic infiltration of tubules and localization of bacteria. Virchows Arch A Pathol Anat Histopathol 1988; 414 (1): 29-37
52. Deguchi T, Kuriyama M, Maeda S, et al. Electron microscopic study of acute retrograde pyelonephritis in mice. Urology 1990; 35 (5): 423-7
53. Chippendale GR, Warren JW, Trifillis AL, et al. Internalization of Proteus mirabilis by human renal epithelial cells. Infect Immun 1994; 62 (8): 3115-21
54. Anderson GG, Martin SM, Hultgren SJ. Host subversion by formation of intracellular bacterial communities in the urinary tract. Microbes Infect 2004; 6 (12): 1094-101
55. Justice SS, Hung C, Theriot JA, et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci U S A 2004; 101 (5): 1333-8
56. Kumon H. Management of biofilm infections in the urinary tract. World J Surg 2000; 24 (10): 1193-6
57. Nickel JC, Olson ME, Costerton JW. Rat model of experimental bacterial prostatitis. Infection 1991; 19 Suppl. 3: S126-30
58. Zogaj X, Bokranz W, Nimtz M, et al. Production of cellulose and curli fimbriae by members of the family Enterobacteriaceae isolated from the human gastrointestinal tract. Infect Immun 2003; 71 (7): 4151-8
59. Sabbuba NA, Mahenthiralingam E, Stickler DJ. Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J Clin Microbiol 2003; 41 (11): 4961-5
60. Jansen AM, Lockatell V, Johnson DE, et al. Mannose-resistant Proteus-like fimbriae are produced by most Proteus mirabilis strains infecting the urinary tract, dictate the in vivo localization of bacteria, and contribute to biofilm formation. Infect Immun 2004; 72 (12): 7294-305
61. Ando E, Monden K, Mitsuhata R, et al. Biofilm formation among methicillin-resistant Staphylococcus aureus isolates from patients with urinary tract infection. Acta Med Okayama 2004; 58 (4): 207-14
62. Debbia EA, Dolcino M, Marchese A, et al. Enhanced biofilm-production in pathogens isolated from patients with rare metabolic disorders. New Microbiol 2004; 27 (4): 361-7
63. Seno Y, Kariyama R, Mitsuhata R, et al. Clinical implications of biofilm formation by Enterococcus faecalis in the urinary tract. Acta Med Okayama 2005; 59 (3): 79-87
64. Bokranz W, Wang X, Tschape H, et al. Expression of cellulose and curli fimbriae by Escherichia coli isolated from the gastro-intestinal tract. J Med Microbiol 2005; 54 (Pt 12): 1171-82
65. Goto T, Nakame Y, Nishida M, et al. In vitro bactericidal activities of beta-lactamases, amikacin, and fluoroquinolones against Pseudomonas aeruginosa biofilm in artificial urine. Urology 1999; 53 (5): 1058-62
66. Goto T, Nakame Y, Nishida M, et al. Bacterial biofilms and catheters in experimental urinary tract infection. Int J Antimicrob Agents 1999; 11 (3-4): 227-31, discussion 237-9
67. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9 (1): 1-9
68. Pea F, Pavan F, Di Qual E, et al. Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500mg b.i.d. for ventilator-associated pneumonia. J Chemother 2003; 15 (6): 563-7
69. Hansen GT, Blondeau JM. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. J Chemother 2005; 17 (5): 484-92
70. Hansen GT, Zhao X, Drlica K, et al. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27 (2): 120-4
71. Fang GD, Brennen C, Wagener M, et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother 1991; 35 (9): 1849-55
72. Peters HJ. Comparison of intravenous ciprofloxacin and mezlocillin in treatment of complicated urinary tract infection. Eur J Clin Microbiol 1986; 5 (2): 253-5
73. Peters HJ. Sequential therapy with ofloxacin in complicated urinary tract infections: a randomized comparative study with ciprofloxacin. Infection 1992; 20 (3): 172-3
74. Naber KG, di Silverio F, Geddes A, et al. Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. J Antimicrob Chemother 1996; 37 Suppl. A: 135-44
75. Mombelli G, Pezzoli R, Pinoja-Lutz G, et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med 1999; 159 (1): 53-8
76. McCue JD. Complicated, recurrent, and geriatric UTI. Contemp Urol 1995; Suppl.: 10-7
77. McCue JD, Gaziano P, Orders D. A randomised controlled trial of ofloxacin 200mg 4 times daily or twice daily vs ciprofloacin 500mg twice daily in elderly nursing home patients with complicated UTI. Drugs 1995; 49 Suppl. 2: 368-73
78. Whitby M, Angus L, Nimmo G, et al. Complicated urinary infection in spinal injury patients: fleroxacin compared with ciprofloxacin. Chemotherapy 1996; 42 (6): 468-72
79. Pisani E, Bartoletti R, Trinchieri A, et al. Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study. J Chemother 1996; 8 (3): 210-3
80. Raz R, Naber KG, Raizenberg C, et al. Ciprofloxacin 250mg twice daily versus ofloxacin 200mg twice daily in the treatment of complicated urinary tract infections in women. Eur J Clin Microbiol Infect Dis 2000; 19 (5): 327-31
81. Krcmery S, Naber KG. Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group. Int J Antimicrob Agents 1999; 11 (2): 133-8
82. Frankenschmidt A, Naber KG, Bischoff W, et al. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections. J Urol 1997; 158 (4): 1494-9
83. Cox CE, Marbury TC, Pittman WG, et al. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther 2002; 24 (2): 223-36
84. Talan DA, Klimberg IW, Nicolle LE, et al. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol 2004; 171 (2 Pt 1): 734-9
85. Matsumoto T, Kumazawa J, Ueda S, et al. Treatment of complicated urinary tract infections with ofloxacin following an aminoglycoside. Chemotherapy 1991; 37 Suppl. 1: 60-7
86. Schalkhauser K. Comparison of i.v. ofloxacin and piperacillin in the treatment of complicated urinary tract infections. J Antimicrob Chemother 1990; 26 Suppl. D: 93-7
87. Cox CE. Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections. Am J Med 1993; 94 (3A): 118S-25S
88. Pittman W, Moon JO, Hamrick Jr LC, et al. Randomized double-blind trial of high- and low-dose fleroxacin versus norfloxacin for complicated urinary tract infection. Am J Med 1993; 94 (3A): 101S-4S
89. Gelfand MS, Simmons BP, Craft RB, et al. A sequential study of concenintravenous and oral fleroxacin in the treatment of complicated urinary tract infection. Am J Med 1993; 94 (3A): 126S-30S
90. Giamarellou H. Fleroxacin in complicated urinary tract infections. Chemotherapy 1996; 42 Suppl. 1: 17-27
91. Nicolle LE, Louie TJ, Dubois J, et al. Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim- sulfamethoxazole. Antimicrob Agents Chemother 1994; 38 (6): 1368-73
92. Hoepelman IM, Havinga WH, Benne RA, et al. Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections. Eur J Clin Microbiol Infect Dis 1993; 12 (5): 343-7
93. Gottlieb PL. Comparison of enoxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with complicated urinary tract infection. Clin Ther 1995; 17 (3): 493-502
94. Klimberg IW, Cox CE, 2nd, et al. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 1998; 51 (4): 610-5
95. Peng MY. Randomized, double-blind, comparative study of levofloxacin and ofloxacin in the treatment of complicated urinary tract infections. J Microbiol Immunol Infect 1999; 32 (1): 33-9
96. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepaflox-acin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44 (10): 2600-3
97. Naber K. Antibacterial activity of antibacterial agents in urine: an overview of applied methods. In: Bergan T, editor. Urinary tract infections. Basel, Freiburg, Paris, London, New York: Karger, 1997: 74-83
98. Wagenlehner F, Tischmeyer, U, Kinzig-Schippers, M, Sörgel, F, Wagenlehner, C, Naber, KG. Plasma concentrations, urinary excretion and bactericidal activity of ciproloxacin XR (1,000mg) versus levofloxacin (500mg) in healthy volunteers receiving a single oral dose. 24th International Congress of Chemotherapy; 2005 June 4-6; Manila
99. Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, et al. Pharmacokinetics of ciprofloxacin XR (1000mg) versus levofloxacin (500mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006; 27 (1): 7-14
100. Boy D, Well M, Kinzig-Schippers M, et al. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004; 23 Suppl. 1: S6-16
101. Stein GE, Schooley S. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers. Int J Antimicrob Agents 2004; 24 (2): 168-72
102. Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, et al. Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2006; 50 (11): 3947-9
103. Allen A, Bygate E, Oliver S, et al. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob Agents Chemother 2000; 44 (6): 1604-8
104. Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001; 40 (3): 169-87
105. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother 1997; 39 Suppl. B: 75-80
106. Richard GA, Klimberg IN, Fowler CL, et al. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998; 52 (1): 51-5
107. Naber KG, Bartnicki A, Bischoff W, et al. Gatifloxacin 200mg or 400mg once daily is as effective as ciprofloxacin 500mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents 2004; 23 Suppl. 1: S41-53
108. Data on file, Bayer Healthcare
109. Data on file, SmithKline Beecham
110. Persky L, Liesen D, Yangco B. Reduced urosepsis in a veterans' hospital. Urology 1992; 39 (5): 443-5